Eli Lilly's U.S. prescriptions for its Zepbound obesity shot have surpassed Wegovy since mid-March in its biggest market.

The Danish company said Jorgensen is leaving by mutual agreement with the board, though he’ll continue as chief 'for a period ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first quarter 20245 investor ...

U.S.-listed shares of Novo Nordisk declined in premarket trading Friday on the surprise news that CEO Lars Fruergaard Jørgensen is stepping down from the maker of blockbuster weight-loss drugs Wegovy ...